AM580, a Stable Benzoic Derivative of Retinoic Acid, Has Powerful and Selective Cyto-Differentiating Effects on Acute Promyelocytic Leukemia Cells

• Published in: Blood 1996-02, Vol.87 (4), p.1520-1531
• Main Authors: Gianni, Maurizio, Calzi, Marco Li, Terao, Mineko, Guiso, Giovanna, Caccia, Silvio, Barbui, Tiziano, Rambaldi, Alessandro, Garattini, Enrico
• Format: Article
• Language: English
• Subjects: Alkaline Phosphatase - genetics; Antigens, CD - metabolism; Antigens, Differentiation, Myelomonocytic - metabolism; Antineoplastic agents; Antineoplastic Agents - pharmacology; Benzoates - pharmacology; Biological and medical sciences; Cell Differentiation - drug effects; Gene Expression - drug effects; Gene Expression Regulation, Neoplastic - drug effects; General aspects; Granulocyte Colony-Stimulating Factor - pharmacology; Granulocytes - cytology; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute - drug therapy; Leukemia, Promyelocytic, Acute - pathology; Macrophage-1 Antigen - metabolism; Medical sciences; Neoplasm Proteins - physiology; Oncogene Proteins, Fusion - physiology; Pharmacology. Drug treatments; Receptors, Retinoic Acid - physiology; RNA, Messenger - genetics; Sialic Acid Binding Ig-like Lectin 3; Tetrahydronaphthalenes - pharmacology; Transcriptional Activation; Tretinoin - analogs & derivatives; Tretinoin - pharmacology
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V87.4.1520.bloodjournal8741520

All-trans retinoic acid (ATRA) is successfully used in the cyto-differentiating treatment of acute promyelocytic leukemia (APL). Paradoxically, APL cells express PML-RAR, an aberrant form of the retinoic acid receptor type α (RARα) derived from the leukemia-specific t(15;17) chromosomal translocation. We show here that AM580, a stable retinobenzoic derivative originally synthesized as a RARα agonist, is a powerful inducer of granulocytic maturation in NB4, an APL-derived cell line, and in freshly isolated APL blasts. After treatment of APL cells with AM580 either alone or in combination with granulocyte colony-stimulating factor (G-CSF), the compound induces granulocytic maturation, as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to produce similar effects. By contrast, AM580 is not so effective as ATRA in modulating the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease. In NB4 cells, two other synthetic nonselective RAR ligands are capable of inducing LAP as much as AM580, whereas RARβ- or RARγ-specific ligands are totally ineffective. These results show that AM580 is more powerful than ATRA in modulating the expression of differentiation antigens only in cells in which PML-RAR is present. Binding experiments, using COS-7 cells transiently transfected with PML-RAR and the normal RARα, show that AM580 has a lower affinity than ATRA for both receptors. However, in the presence of PML-RAR, the synthetic retinoid is a much better transactivator of retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RARα, AM580 and ATRA have similar activity. This may explain the strong cyto-differentiating potential of AM580 in PML-RAR-containing leukemic cells.